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ABSTRACT 
Three human term placentas have been perfused in 
situ with labeled pregnenolone. Perfusions were per- 
formed at the time of elective repeat cesarean section, 
prior to the onset of labor. Placentas and venous 
effluents were separately analyzed. As is true in 
midtrimester placentas, rapid and extensive conversion 
to progesterone was effected by the placenta. In 
addition to progesterone, 6@-hydroxyprogesterone was 
identified. 
The rapid and extensive in situ conversion of -- 
labeled pregnenolone') to progesterone in the midterm 
human placenta has been demonstrated (1). The capacity 
for enzyme nmaturation' in various human fetal and 
infant tissues both with advancing gestation and during 
the neonatal period has also been suggested (2, 3). 
The following experiment was designed in an effort 
to assess the qualitative and quantitative aspects 
of in vivo human placental steroidogenesis at term -- 
utilizing pregnenolone as substrate, as well as to 
develop a satisfactory model for the study of in situ -- 
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steroidogenesis in the human term placenta utilizing 
8:l 
a variety of substrates. 
METHODS AND MATERIALS 
Perfusion Technique: Studies were carried out on 
three patients scheduled for elective repeat cesarean 
section at term, with no other medical or obstetric 
complication of the present pregnancy. 
Under tetracaine hydrochloride spinal anesthesia, 
following delivery of the infant by cesarean section, 
a sterile infant feeding tube was inserted into one 
umbilical artery and an adult feeding tube into the 
umbilical vein. Citrated whole blood, typed and 
cross-matched against that of the mother, was infused 
into the umbilical arterial catheter. At one minute 
intervals, over a period of 7 minutes, 0.1 ml of a 50% 
ethanol in distilled water (v/v) solution of isotopic 
pregnenolone was injected into the arterial catheter. 
This was followed by 2 minutes of additional blood 
perfusion without further injection of steroid. The 
venous effluent was collected in a flask of absolute 
ethanol. 
Materials: All organic solvents were redistilled 
prior to use. Crystalline steroid standards were 
recrystallized prior to use and corrected melting 
points determined. 
Pregnenolone-7a-3H, Lot No. 66-156A-lg2) with 
a specific activity (S-A.) of 31.6 mc/mg and preg- 
nenolone-4-14C, Lot No. 79-239A-402) with a S.A. of 
14.5 mc/mg were purified utilizing thin-layer chroma- 
tography on Silica gel G3) in the following solvent 
systems: cyclohexane: ethyl acetate: ethanol, 9: 9: 2 
(Rf = 0.57) and benzene: ethanol, 9: 1 (Rf = 0.38). 
An aliquot of this purified material was then mixed 
with authentic carrier and recrystallized from ethanol 
and methanol. Initial recrystallization demonstrated 
agreement within 5% of that of the specific activity 
of the starting material. 
The amount of pregnenolone-7a-3H perfused 
(Experiments 1 and 2) was 5.0 and 5.8 uc, and that 
of pregnenolone-4-14c (Experiment 3) was 2.0 WC. 
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Extraction and Purification: The umbilical venous 
effluent was collected dropwise in 200 ml of ethanol, 
which was constantly agitated. After completion of 
the perfusion, the placenta was manually removed, 
membranes and cord immediately dissected away and the 
placenta homogenized in 400 ml of ethanol. Further 
extraction with ethanol, and methanol precipitation 
were carried out as described by Mikhail et al. (4). 
Separation of "free" from "conjugated" radio- 
active material was carried out in a countercurrent 
fashion using a dichloromethane-water partition, with 
three separatory funnels and six lower-phase transfers. 
The volume of each phase was 50 ml. 
An outline of the extraction and identification 
procedures employed on the dichloromethane fraction 
is shown in Figure 1. 
Twenty-four hour urine specimens were collected 
for three days following the procedure, and aliquots 
of each days urine assessed for their radioactive 
content. 
Countercurrent Distribution (C.C.D.): In all cases, 
24 transfer distributions were carried out in a manual 
Craig-Post apparatus using the following solvent 
systems: 
No. 1. Cyclohexane, ethyl acetate, ethanol, 
water (7:3:5:5) 
Petroleum ether, methanol, water 
(10:7:3) 
n-Hexane, ethanol, water (25:12.1:12.9) 
Methanol, water, carbon tetrachloride 
(4:1:5) 
Cyclohexane, ethanol, water (10:9:1) 







Derivative Formation: Acetylation was carried out 
with acetic anhydride in anhydrous pyridine (1:2) at 
room temperature overnight. Formation of digitonides 
was performed utilizing the method of Frame (5) and 
of the bisthiosemicarbazone derivative utilizing the 
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Estimation of C-21 Steroids: The 01, B-unsaturated 
3-ketosteroids were detected on thin-layer chromato- 
grams by ultraviolet light and measured by ultra- 
violet absorption at 240 rnp using the Allen correction 
formula (7). For detection of 3@-hydroxy-A5-steroids 
on thin-layer chromatograms, a phosphomolybdic acid 
spray was employed, and their measurement was carried 
out by the method of Oertel and Eik-Nes (8). 
Recrystallization to Constant Specific Activity: 
Appropriate carrier steroid was added to the isolated 
radioactive material derived from the final counter- 
current distribution. For each isolated compound, 
successive recrystallizations from at least three 
different solvent systems were performed. The carrier 
was estimated gravimetrically. 
Countinq Procedure: Counting was carried out in an 
automated two channel Packard Tri-Carb liquid 
scintillation counter (series 3000). The tritium 
window was set from 10 to 100% of the analyzer full 
scale with a relative gain of 60, and the carbon 
window was set from 10 to 70% of full scale with a 
relative gain of 5. Samples were counted in 10 ml 
toluene containing 3.0 g/l PPO (2,5_diphenyloxazole) 
and 100 mg/l POPOP (1, 4-bis-2-(4-methyl-5-phenyl- 
oxazolyl) benzene). Urine samples (0.5 ml) were 
first dissolved in one ml methanol and then 10 ml of 
the above toluene scintillant solution added. 
Appropriate quench corrections were performed using 
an internal standard technique. Counting efficiencies 
were monitored utilizing standards prepared in the 
same manner as the samples. 
RESULTS 
As seen in Table 1, 47.7 to 66.3 percent of the 
perfused radioactivity was recovered from the three 
sources in which it was measured. 
Table 2 illustrates the distribution of "free" 
(dichloromethane-soluble) and "conjugated" (water- 
soluble) metabolites in the placentas and venous 
effluents. It can be seen that 0.3 to 5.0 percent 
66 STEROIDS 8:l 
Table 1 
Recovery of Injected Radioactivity Following in situ Perfusion -- 
of Human Term Placentas with Labeled Pregnenolone. 
Amount Venous Maternal Percent 
Injected Placenta Effluent urine Injected 
Experiment (CLc) (d.p.m.) (d.p.m.) (d.p.m.) dose 
1 5.0 2,081,032 679,611 2,528,690 47.7 
2 5.8 5,751,597 158,894 2,464,209 66.3 
3 2.0 728,423 1,105,879 732,088 59.3 
Table 2 
Distribution of Dichloromethane-Soluble and Water-Soluble 
Radioactive Material Following in situ Perfusion of A- 























of the radioactive material in the placenta, and 0.8 
to 14.7 percent of that in the venous effluent could 
not be removed by dichloromethane from the aqueous 
phase. The material which remained in the aqueous 
phase was not analyzed further. 
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The distribution of the major radioactive 
components in the "free" material in both placenta 
and venous effluent found after perfusion with 
pregnenolone-7a 3H and pregnenolone-4-14C is presented 
in Table 3. Based on calculations derived from the 
final countercurrent distributions, approximately 60 
to 84 percent of the radioactive material present in 
the 1' free" fraction of placentas was recovered as 
progesterone, only 3 to 30 percent as unchanged 
pregnenolone. In addition, between 17 and 34 percent 
of the radioactive material recovered from the venous 
effluent was progesterone and 53 to 73 percent as 
pregnenolone. 18.6, 26.1 and 10.3 percent of the 
total injected dose of the pregnenolone perfused was 
recovered as progesterone in each of the three 
experiments. 
Table 3 
Distribution of progesterone and unchanged pregnenolone 
in placentas and venous effluents expressed as percentage 
of recovered radioactivity. 
Placenta 
Exp. Progesterone Pregnenolone 
Percent ’ Percent 
1 1 82.6 3.4 
1 
j 2 60.1 29.6 
13 84.1 6.8 / 
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The recovery data presented for progesterone and 
pregnenolone are derived from the final countercurrent 
distributions since, on subsequent recrystallization 
there was no appreciable decrease in S.A. from the 
anticipated values. However, upon recrystallization 
of 6@-hydroxyprogesterone, a significant drop was 
noted. Because of a relative paucity of radioactive 
material in the 6@-hydroxyprogesterone-like fraction, 
material from this fraction in both placenta and 
venous effluent was pooled in experiments 1 and 2 
prior to recrystallization. Based on the final counter- 
current and recrystallization data, and assuming a 
corresponding decrease in S.A. in both placenta and 
venous effluent, the 6@-hydroxyprogesterone represented 
approximately 1.9, 1.9, and 1.5 percent of the radio- 
active material recovered from the placentas and 2.1, 
3.7, and 0.4 percent of that from the venous effluents. 
As noted in Fig. 1, identification of progesterone, 
GS-hydroxyprogesterone and precursor pregnenolone was 
based on distribution in multiple countercurrent 
systems. In each instance, agreement was noted with 
the authentic carrier substance. Following counter- 
current distribution, recrystallization to constant 
S.A. was effected. The data on recrystallization of 
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the starting pregnenolone (as the acetate), pro- 
gesterone and 6f3-hydroxyprogesterone is presented 
in Table 4. 
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Additionally, as seen in Fig. 1, following 
recrystallization, the bisthiosemicarbazone deriv- 
ative of progesterone was formed and redistributed 
in C.C.D. System No. 4. Again, excellent agreement 
with carrier was noted. 
DISCUSSION 
Like the midtrimester placenta, the human term 
placenta has the capacity of converting the bulk of 
perfused pregnenolone to progesterone in vivo and of -- 
secreting the progesterone so formed into the fetal 
compartment. Also similar to the situation obtain- 
ing in the midtrimester placenta, this progesterone 
formation is both rapid and extensive. 
The term placenta also has the capacity of 
converting circulating cholesterol to pregnenolone (9). 
In addition, there is extensive desulfurylation of 
pregnenolone sulfate, perfused in situ to the human -- 
term placenta (lo), and conversion of the bulk of 
the pregnenolone so formed to progesterone. Thus 
the relative contribution to placental progesterone 
production by 1) pregnenolone produced in the 
placenta from circulating cholesterol, 2) circulating 
pregnenolone sulfate (which has been demonstrated 
in both pooled peripheral plasma (11) and umbilical 
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cord blood (12) and 3) "free" circulating pregneno- 
lone (which could not be found in umbilical cord 
blood although free 17c-hydroxypregnenolone was 
detected (12)), remains to be ascertained. 
The finding by Cassmer (13) of only slight 
diminution of urinary pregnanediol excretion 
following interruption of umbilical circulation at 
midpregnancy, coupled with similar pregnanediol 
excretion patterns in pregnancies marked by 
anencephalic fetuses (14) or intrauterine death 
(15-17), suggests that the progesterone precursor 
contribution from the fetal compartment is limited. 
Further, the in vitro demonstration of conversion *-- 
of acetate and mevalonate to squalene and cholesterol 
(18, 19) and of cholesterol to pregnenolone and 
progesterone (20, 21) leaves unresolved the relative 
contributions of de novo glandular synthesis and -- 
circulating precursors to the placental elaboration 
of progesterone. 
Coupled with data pertaining to the fate of 
dehydroepiandrosterone and its sulfate in pregnancy 
(22-25), the findings from the human term placental 
perfusions described above suggest utilization of a 
variety of circulating A5 38 hydroxylated compounds 
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in placental steroidogenesis. 
Recent studies by Bird et al. (26) have 
demonstrated that in the seventeenth to twenty- 
first weeks of pregnancy, some progesterone cir- 
culating in the fetal compartment is converted to 
a variety of free and conjugated steroids, including 
corticosteroids in the fetal adrenal gland. Whether 
this utilization of placental progesterone by the 
fetus occurs in vivo at term remains to be -- 
ascertained. 
Incubations of term placental tissue have 
demonstrated 6@- (27), 16a- (28, 17a- (29) and 20~ (30) 
hydroxylation of progesterone when labeled progesterone 
was used as substrate. Desmolase activity, with 
conversion of labeled progesterone to adrostenedione 
has also been demonstrated in vitro (28, 31). In vitro -- -- 
placental perfusion of progesterone also demonstrated 
formation of 6-ketoprogesterone (28). 
In addition, a variety of progesterone metabo- 
lites have been isolated from human placentas. These 
include 20a- and 20@-hydroxy-pregn-4-ene-3-one, 
pregnanediol, 38 hydroxy-5-cz-pregnane-20-one and 5a- 
pregnane-38, 20a-diol (29-31). 
Following digitonin precipitation in the present 
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experiments, no precipitable radioactive material was 
found other than the precursor pregnenolone. This 
suggests that, under the conditions of these experi- 
ments, no 3B-hydroxy-A5 metabolites were present. 
Further, neither 16~~ nor 17~ hydroxyprogesterone, 
androstenedione, nor 20a- or 20@-hydroxy-pregn-4-ene- 
3-one could be detected. In addition, because of 
the finding of placental 6o-hydroxylation of 
estrogens (36, 37) 6c+hydroxyprogesterone was also 
sought, but was not detected. 
Non-digitonin precipitable radioactive material 
which had the mobility of 6B-hydroxyprogesterone in 
two countercurrent systems was detected. It was 
possible to further identify this material as 6B- 
hydroxyprogesterone by recrystallization to constant 
specific activity. However, as mentioned earlier, 
a significant decrease in specific activity from 
starting material to final crystals was observed. 
In addition, the countercurrent distribution curves 
of the 6@-hydroxyprogesterone-like material were 
"broader" than those of the carrier material. These 
observations suggest the presence of another 
metabolite with similar chromatographic mobilities 
to that of 6@-hydroxyprogesterone in the counter- 
73 
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current systems utilized. Insufficient material 
precluded further analysis of this fraction. Six 8- 
hydroxylation of progesterone has been reported 
after incubation with stromal and corpus luteal 
tissue from human ovaries (38) and hypertrophic 
and carcinomatous human prostatic tissue, (39) as 
well as in placental incubation (27). Increasing 
urinary excretion of 6-oxygenated metabolites of 
progesterone with advancing gestational age has been 
reported by Fotherby et al. (40). Zander (41), and 
Bird et al.(26) have demonstrated the human fetal 
capacity to form 6S-hydroxyprogesterone. Thus, both 
fetal and placental 6@-hydroxyprogesterone may con- 
tribute to this 6-oxygenated metabolite pool. 
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